nodes	percent_of_prediction	percent_of_DWPC	metapath
Pergolide—HTR2A—vein—ovarian cancer	0.00957	0.0818	CbGeAlD
Pergolide—DRD4—testis—ovarian cancer	0.00452	0.0386	CbGeAlD
Pergolide—ADRA1D—epithelium—ovarian cancer	0.00398	0.034	CbGeAlD
Pergolide—DRD5—female reproductive system—ovarian cancer	0.00369	0.0315	CbGeAlD
Pergolide—HTR2B—myometrium—ovarian cancer	0.00353	0.0301	CbGeAlD
Pergolide—DRD5—female gonad—ovarian cancer	0.00335	0.0287	CbGeAlD
Pergolide—ADRA1D—female reproductive system—ovarian cancer	0.00296	0.0253	CbGeAlD
Pergolide—KCNH2—myometrium—ovarian cancer	0.00281	0.024	CbGeAlD
Pergolide—ADRA2C—myometrium—ovarian cancer	0.00277	0.0237	CbGeAlD
Pergolide—HTR2B—uterine cervix—ovarian cancer	0.00274	0.0234	CbGeAlD
Pergolide—HTR2B—decidua—ovarian cancer	0.00261	0.0223	CbGeAlD
Pergolide—HTR2B—endometrium—ovarian cancer	0.00248	0.0212	CbGeAlD
Pergolide—HTR2B—uterus—ovarian cancer	0.00229	0.0195	CbGeAlD
Pergolide—ADRA1A—epithelium—ovarian cancer	0.00229	0.0195	CbGeAlD
Pergolide—HTR1B—female reproductive system—ovarian cancer	0.00228	0.0195	CbGeAlD
Pergolide—ADRA2A—myometrium—ovarian cancer	0.00221	0.0189	CbGeAlD
Pergolide—HTR1D—female reproductive system—ovarian cancer	0.00221	0.0189	CbGeAlD
Pergolide—KCNH2—uterine cervix—ovarian cancer	0.00219	0.0187	CbGeAlD
Pergolide—HTR2C—female reproductive system—ovarian cancer	0.00219	0.0187	CbGeAlD
Pergolide—ADRA2C—uterine cervix—ovarian cancer	0.00216	0.0185	CbGeAlD
Pergolide—ADRA2C—decidua—ovarian cancer	0.00206	0.0176	CbGeAlD
Pergolide—HTR2B—female reproductive system—ovarian cancer	0.00206	0.0176	CbGeAlD
Pergolide—KCNH2—endometrium—ovarian cancer	0.00198	0.0169	CbGeAlD
Pergolide—ADRA2C—endometrium—ovarian cancer	0.00195	0.0167	CbGeAlD
Pergolide—HTR2B—vagina—ovarian cancer	0.00186	0.0159	CbGeAlD
Pergolide—KCNH2—uterus—ovarian cancer	0.00182	0.0156	CbGeAlD
Pergolide—HTR2A—embryo—ovarian cancer	0.00181	0.0155	CbGeAlD
Pergolide—ADRA2C—uterus—ovarian cancer	0.0018	0.0154	CbGeAlD
Pergolide—ADRA2A—uterine cervix—ovarian cancer	0.00172	0.0147	CbGeAlD
Pergolide—ADRA2A—decidua—ovarian cancer	0.00164	0.014	CbGeAlD
Pergolide—KCNH2—female reproductive system—ovarian cancer	0.00164	0.014	CbGeAlD
Pergolide—ADRA2A—endometrium—ovarian cancer	0.00156	0.0133	CbGeAlD
Pergolide—KCNH2—bone marrow—ovarian cancer	0.00155	0.0132	CbGeAlD
Pergolide—KCNH2—female gonad—ovarian cancer	0.00149	0.0128	CbGeAlD
Pergolide—KCNH2—vagina—ovarian cancer	0.00148	0.0127	CbGeAlD
Pergolide—HTR2A—epithelium—ovarian cancer	0.00148	0.0126	CbGeAlD
Pergolide—ADRA2C—female gonad—ovarian cancer	0.00147	0.0126	CbGeAlD
Pergolide—ADRA2C—vagina—ovarian cancer	0.00146	0.0125	CbGeAlD
Pergolide—ADRA2A—gonad—ovarian cancer	0.00145	0.0124	CbGeAlD
Pergolide—ADRA2A—uterus—ovarian cancer	0.00144	0.0123	CbGeAlD
Pergolide—DRD2—testis—ovarian cancer	0.00134	0.0115	CbGeAlD
Pergolide—KCNH2—testis—ovarian cancer	0.00132	0.0113	CbGeAlD
Pergolide—ADRA2C—testis—ovarian cancer	0.00131	0.0112	CbGeAlD
Pergolide—ADRA2A—female reproductive system—ovarian cancer	0.00129	0.011	CbGeAlD
Pergolide—HTR2A—gonad—ovarian cancer	0.00123	0.0105	CbGeAlD
Pergolide—HTR2B—lymph node—ovarian cancer	0.0012	0.0103	CbGeAlD
Pergolide—ADRA2A—female gonad—ovarian cancer	0.00117	0.01	CbGeAlD
Pergolide—ADRA2A—vagina—ovarian cancer	0.00117	0.00998	CbGeAlD
Pergolide—HTR2A—female reproductive system—ovarian cancer	0.0011	0.00938	CbGeAlD
Pergolide—ADRA2A—testis—ovarian cancer	0.00104	0.0089	CbGeAlD
Pergolide—CYP3A4—female reproductive system—ovarian cancer	0.00102	0.00868	CbGeAlD
Pergolide—CYP2D6—female reproductive system—ovarian cancer	0.001	0.00855	CbGeAlD
Pergolide—HTR2A—vagina—ovarian cancer	0.000993	0.00848	CbGeAlD
Pergolide—KCNH2—lymph node—ovarian cancer	0.000959	0.0082	CbGeAlD
Pergolide—ADRA2C—lymph node—ovarian cancer	0.000946	0.00809	CbGeAlD
Pergolide—CYP2D6—female gonad—ovarian cancer	0.00091	0.00778	CbGeAlD
Pergolide—HTR2A—testis—ovarian cancer	0.000886	0.00757	CbGeAlD
Pergolide—CYP2D6—testis—ovarian cancer	0.000807	0.0069	CbGeAlD
Pergolide—ADRA2A—lymph node—ovarian cancer	0.000755	0.00645	CbGeAlD
Pergolide—Pancreatitis—Epirubicin—ovarian cancer	0.000466	0.00054	CcSEcCtD
Pergolide—Shock—Paclitaxel—ovarian cancer	0.000465	0.000539	CcSEcCtD
Pergolide—Dizziness—Vinorelbine—ovarian cancer	0.000465	0.000539	CcSEcCtD
Pergolide—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000465	0.000539	CcSEcCtD
Pergolide—Hypokalaemia—Doxorubicin—ovarian cancer	0.000463	0.000537	CcSEcCtD
Pergolide—Angina pectoris—Epirubicin—ovarian cancer	0.000463	0.000537	CcSEcCtD
Pergolide—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000463	0.000537	CcSEcCtD
Pergolide—Tachycardia—Paclitaxel—ovarian cancer	0.000461	0.000535	CcSEcCtD
Pergolide—Bronchitis—Epirubicin—ovarian cancer	0.000457	0.00053	CcSEcCtD
Pergolide—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000457	0.00053	CcSEcCtD
Pergolide—Anaemia—Docetaxel—ovarian cancer	0.000454	0.000526	CcSEcCtD
Pergolide—Anorexia—Paclitaxel—ovarian cancer	0.000451	0.000522	CcSEcCtD
Pergolide—Gastritis—Doxorubicin—ovarian cancer	0.00045	0.000522	CcSEcCtD
Pergolide—Vomiting—Vinorelbine—ovarian cancer	0.000447	0.000518	CcSEcCtD
Pergolide—Dysuria—Epirubicin—ovarian cancer	0.000444	0.000515	CcSEcCtD
Pergolide—Rash—Vinorelbine—ovarian cancer	0.000443	0.000514	CcSEcCtD
Pergolide—Dermatitis—Vinorelbine—ovarian cancer	0.000443	0.000513	CcSEcCtD
Pergolide—Abdominal distension—Doxorubicin—ovarian cancer	0.000443	0.000513	CcSEcCtD
Pergolide—Hypotension—Paclitaxel—ovarian cancer	0.000442	0.000512	CcSEcCtD
Pergolide—Headache—Vinorelbine—ovarian cancer	0.00044	0.00051	CcSEcCtD
Pergolide—Syncope—Docetaxel—ovarian cancer	0.00044	0.00051	CcSEcCtD
Pergolide—Dysphagia—Doxorubicin—ovarian cancer	0.00044	0.00051	CcSEcCtD
Pergolide—Asthma—Doxorubicin—ovarian cancer	0.00044	0.00051	CcSEcCtD
Pergolide—Influenza—Doxorubicin—ovarian cancer	0.00044	0.00051	CcSEcCtD
Pergolide—Leukopenia—Docetaxel—ovarian cancer	0.00044	0.000509	CcSEcCtD
Pergolide—Pollakiuria—Epirubicin—ovarian cancer	0.000439	0.000509	CcSEcCtD
Pergolide—Eosinophilia—Doxorubicin—ovarian cancer	0.000435	0.000505	CcSEcCtD
Pergolide—Palpitations—Docetaxel—ovarian cancer	0.000434	0.000503	CcSEcCtD
Pergolide—Weight increased—Epirubicin—ovarian cancer	0.000433	0.000501	CcSEcCtD
Pergolide—Loss of consciousness—Docetaxel—ovarian cancer	0.000432	0.0005	CcSEcCtD
Pergolide—Pancreatitis—Doxorubicin—ovarian cancer	0.000431	0.0005	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000431	0.000499	CcSEcCtD
Pergolide—Weight decreased—Epirubicin—ovarian cancer	0.00043	0.000498	CcSEcCtD
Pergolide—Hyperglycaemia—Epirubicin—ovarian cancer	0.000429	0.000497	CcSEcCtD
Pergolide—Cough—Docetaxel—ovarian cancer	0.000428	0.000497	CcSEcCtD
Pergolide—Angina pectoris—Doxorubicin—ovarian cancer	0.000428	0.000497	CcSEcCtD
Pergolide—Insomnia—Paclitaxel—ovarian cancer	0.000428	0.000496	CcSEcCtD
Pergolide—Pneumonia—Epirubicin—ovarian cancer	0.000426	0.000494	CcSEcCtD
Pergolide—Convulsion—Docetaxel—ovarian cancer	0.000425	0.000493	CcSEcCtD
Pergolide—Paraesthesia—Paclitaxel—ovarian cancer	0.000425	0.000492	CcSEcCtD
Pergolide—Hypertension—Docetaxel—ovarian cancer	0.000424	0.000491	CcSEcCtD
Pergolide—Bronchitis—Doxorubicin—ovarian cancer	0.000423	0.00049	CcSEcCtD
Pergolide—Dyspnoea—Paclitaxel—ovarian cancer	0.000421	0.000489	CcSEcCtD
Pergolide—Somnolence—Paclitaxel—ovarian cancer	0.00042	0.000487	CcSEcCtD
Pergolide—Arthralgia—Docetaxel—ovarian cancer	0.000418	0.000484	CcSEcCtD
Pergolide—Myalgia—Docetaxel—ovarian cancer	0.000418	0.000484	CcSEcCtD
Pergolide—Chest pain—Docetaxel—ovarian cancer	0.000418	0.000484	CcSEcCtD
Pergolide—Nausea—Vinorelbine—ovarian cancer	0.000418	0.000484	CcSEcCtD
Pergolide—Renal failure—Epirubicin—ovarian cancer	0.000417	0.000483	CcSEcCtD
Pergolide—Dyspepsia—Paclitaxel—ovarian cancer	0.000416	0.000482	CcSEcCtD
Pergolide—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000415	0.000481	CcSEcCtD
Pergolide—Jaundice—Epirubicin—ovarian cancer	0.000413	0.000479	CcSEcCtD
Pergolide—Urinary tract infection—Epirubicin—ovarian cancer	0.000412	0.000477	CcSEcCtD
Pergolide—Conjunctivitis—Epirubicin—ovarian cancer	0.000412	0.000477	CcSEcCtD
Pergolide—Dysuria—Doxorubicin—ovarian cancer	0.000411	0.000477	CcSEcCtD
Pergolide—Decreased appetite—Paclitaxel—ovarian cancer	0.000411	0.000476	CcSEcCtD
Pergolide—Dry mouth—Docetaxel—ovarian cancer	0.000409	0.000474	CcSEcCtD
Pergolide—Sweating—Epirubicin—ovarian cancer	0.000406	0.000471	CcSEcCtD
Pergolide—Pollakiuria—Doxorubicin—ovarian cancer	0.000406	0.000471	CcSEcCtD
Pergolide—Pain—Paclitaxel—ovarian cancer	0.000404	0.000469	CcSEcCtD
Pergolide—Constipation—Paclitaxel—ovarian cancer	0.000404	0.000469	CcSEcCtD
Pergolide—Haematuria—Epirubicin—ovarian cancer	0.000404	0.000468	CcSEcCtD
Pergolide—Confusional state—Docetaxel—ovarian cancer	0.000404	0.000468	CcSEcCtD
Pergolide—Oedema—Docetaxel—ovarian cancer	0.000401	0.000464	CcSEcCtD
Pergolide—Weight increased—Doxorubicin—ovarian cancer	0.0004	0.000464	CcSEcCtD
Pergolide—Epistaxis—Epirubicin—ovarian cancer	0.0004	0.000463	CcSEcCtD
Pergolide—Infection—Docetaxel—ovarian cancer	0.000398	0.000461	CcSEcCtD
Pergolide—Weight decreased—Doxorubicin—ovarian cancer	0.000398	0.000461	CcSEcCtD
Pergolide—Sinusitis—Epirubicin—ovarian cancer	0.000398	0.000461	CcSEcCtD
Pergolide—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000397	0.00046	CcSEcCtD
Pergolide—Pneumonia—Doxorubicin—ovarian cancer	0.000394	0.000457	CcSEcCtD
Pergolide—Shock—Docetaxel—ovarian cancer	0.000394	0.000457	CcSEcCtD
Pergolide—Thrombocytopenia—Docetaxel—ovarian cancer	0.000392	0.000455	CcSEcCtD
Pergolide—Tachycardia—Docetaxel—ovarian cancer	0.000391	0.000453	CcSEcCtD
Pergolide—Feeling abnormal—Paclitaxel—ovarian cancer	0.00039	0.000452	CcSEcCtD
Pergolide—Bradycardia—Epirubicin—ovarian cancer	0.000387	0.000449	CcSEcCtD
Pergolide—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000387	0.000448	CcSEcCtD
Pergolide—Renal failure—Doxorubicin—ovarian cancer	0.000385	0.000447	CcSEcCtD
Pergolide—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000384	0.000446	CcSEcCtD
Pergolide—Jaundice—Doxorubicin—ovarian cancer	0.000382	0.000443	CcSEcCtD
Pergolide—Anorexia—Docetaxel—ovarian cancer	0.000382	0.000443	CcSEcCtD
Pergolide—Rhinitis—Epirubicin—ovarian cancer	0.000381	0.000442	CcSEcCtD
Pergolide—Urinary tract infection—Doxorubicin—ovarian cancer	0.000381	0.000442	CcSEcCtD
Pergolide—Conjunctivitis—Doxorubicin—ovarian cancer	0.000381	0.000442	CcSEcCtD
Pergolide—Hepatitis—Epirubicin—ovarian cancer	0.00038	0.000441	CcSEcCtD
Pergolide—Pharyngitis—Epirubicin—ovarian cancer	0.000378	0.000438	CcSEcCtD
Pergolide—Sweating—Doxorubicin—ovarian cancer	0.000376	0.000436	CcSEcCtD
Pergolide—Oedema peripheral—Epirubicin—ovarian cancer	0.000375	0.000434	CcSEcCtD
Pergolide—Hypotension—Docetaxel—ovarian cancer	0.000374	0.000434	CcSEcCtD
Pergolide—Haematuria—Doxorubicin—ovarian cancer	0.000374	0.000433	CcSEcCtD
Pergolide—Abdominal pain—Paclitaxel—ovarian cancer	0.000374	0.000433	CcSEcCtD
Pergolide—Body temperature increased—Paclitaxel—ovarian cancer	0.000374	0.000433	CcSEcCtD
Pergolide—Epistaxis—Doxorubicin—ovarian cancer	0.00037	0.000429	CcSEcCtD
Pergolide—Sinusitis—Doxorubicin—ovarian cancer	0.000368	0.000426	CcSEcCtD
Pergolide—Visual impairment—Epirubicin—ovarian cancer	0.000367	0.000425	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000365	0.000423	CcSEcCtD
Pergolide—Insomnia—Docetaxel—ovarian cancer	0.000362	0.00042	CcSEcCtD
Pergolide—Paraesthesia—Docetaxel—ovarian cancer	0.00036	0.000417	CcSEcCtD
Pergolide—Bradycardia—Doxorubicin—ovarian cancer	0.000358	0.000415	CcSEcCtD
Pergolide—Dyspnoea—Docetaxel—ovarian cancer	0.000357	0.000414	CcSEcCtD
Pergolide—Somnolence—Docetaxel—ovarian cancer	0.000356	0.000413	CcSEcCtD
Pergolide—Eye disorder—Epirubicin—ovarian cancer	0.000356	0.000412	CcSEcCtD
Pergolide—Tinnitus—Epirubicin—ovarian cancer	0.000355	0.000411	CcSEcCtD
Pergolide—Rhinitis—Doxorubicin—ovarian cancer	0.000353	0.000409	CcSEcCtD
Pergolide—Dyspepsia—Docetaxel—ovarian cancer	0.000353	0.000409	CcSEcCtD
Pergolide—Hepatitis—Doxorubicin—ovarian cancer	0.000352	0.000408	CcSEcCtD
Pergolide—Pharyngitis—Doxorubicin—ovarian cancer	0.000349	0.000405	CcSEcCtD
Pergolide—Decreased appetite—Docetaxel—ovarian cancer	0.000348	0.000404	CcSEcCtD
Pergolide—Oedema peripheral—Doxorubicin—ovarian cancer	0.000347	0.000402	CcSEcCtD
Pergolide—Constipation—Docetaxel—ovarian cancer	0.000343	0.000397	CcSEcCtD
Pergolide—Pain—Docetaxel—ovarian cancer	0.000343	0.000397	CcSEcCtD
Pergolide—Chills—Epirubicin—ovarian cancer	0.000341	0.000396	CcSEcCtD
Pergolide—Arrhythmia—Epirubicin—ovarian cancer	0.00034	0.000394	CcSEcCtD
Pergolide—Visual impairment—Doxorubicin—ovarian cancer	0.000339	0.000393	CcSEcCtD
Pergolide—Asthenia—Paclitaxel—ovarian cancer	0.000339	0.000393	CcSEcCtD
Pergolide—Alopecia—Epirubicin—ovarian cancer	0.000336	0.00039	CcSEcCtD
Pergolide—Pruritus—Paclitaxel—ovarian cancer	0.000334	0.000388	CcSEcCtD
Pergolide—Feeling abnormal—Docetaxel—ovarian cancer	0.00033	0.000383	CcSEcCtD
Pergolide—Eye disorder—Doxorubicin—ovarian cancer	0.000329	0.000381	CcSEcCtD
Pergolide—Tinnitus—Doxorubicin—ovarian cancer	0.000328	0.00038	CcSEcCtD
Pergolide—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000328	0.00038	CcSEcCtD
Pergolide—Flatulence—Epirubicin—ovarian cancer	0.000326	0.000378	CcSEcCtD
Pergolide—Tension—Epirubicin—ovarian cancer	0.000325	0.000377	CcSEcCtD
Pergolide—Dysgeusia—Epirubicin—ovarian cancer	0.000324	0.000376	CcSEcCtD
Pergolide—Diarrhoea—Paclitaxel—ovarian cancer	0.000323	0.000375	CcSEcCtD
Pergolide—Nervousness—Epirubicin—ovarian cancer	0.000322	0.000373	CcSEcCtD
Pergolide—Back pain—Epirubicin—ovarian cancer	0.00032	0.000371	CcSEcCtD
Pergolide—Abdominal pain—Docetaxel—ovarian cancer	0.000317	0.000367	CcSEcCtD
Pergolide—Body temperature increased—Docetaxel—ovarian cancer	0.000317	0.000367	CcSEcCtD
Pergolide—Chills—Doxorubicin—ovarian cancer	0.000316	0.000366	CcSEcCtD
Pergolide—Arrhythmia—Doxorubicin—ovarian cancer	0.000314	0.000364	CcSEcCtD
Pergolide—Dizziness—Paclitaxel—ovarian cancer	0.000313	0.000362	CcSEcCtD
Pergolide—Alopecia—Doxorubicin—ovarian cancer	0.000311	0.000361	CcSEcCtD
Pergolide—Ill-defined disorder—Epirubicin—ovarian cancer	0.000307	0.000356	CcSEcCtD
Pergolide—Anaemia—Epirubicin—ovarian cancer	0.000306	0.000355	CcSEcCtD
Pergolide—Agitation—Epirubicin—ovarian cancer	0.000304	0.000353	CcSEcCtD
Pergolide—Flatulence—Doxorubicin—ovarian cancer	0.000302	0.00035	CcSEcCtD
Pergolide—Tension—Doxorubicin—ovarian cancer	0.000301	0.000349	CcSEcCtD
Pergolide—Vomiting—Paclitaxel—ovarian cancer	0.000301	0.000348	CcSEcCtD
Pergolide—Dysgeusia—Doxorubicin—ovarian cancer	0.0003	0.000348	CcSEcCtD
Pergolide—Malaise—Epirubicin—ovarian cancer	0.000299	0.000346	CcSEcCtD
Pergolide—Rash—Paclitaxel—ovarian cancer	0.000298	0.000345	CcSEcCtD
Pergolide—Dermatitis—Paclitaxel—ovarian cancer	0.000298	0.000345	CcSEcCtD
Pergolide—Nervousness—Doxorubicin—ovarian cancer	0.000298	0.000345	CcSEcCtD
Pergolide—Vertigo—Epirubicin—ovarian cancer	0.000298	0.000345	CcSEcCtD
Pergolide—Syncope—Epirubicin—ovarian cancer	0.000297	0.000344	CcSEcCtD
Pergolide—Leukopenia—Epirubicin—ovarian cancer	0.000296	0.000344	CcSEcCtD
Pergolide—Back pain—Doxorubicin—ovarian cancer	0.000296	0.000344	CcSEcCtD
Pergolide—Headache—Paclitaxel—ovarian cancer	0.000296	0.000343	CcSEcCtD
Pergolide—Palpitations—Epirubicin—ovarian cancer	0.000293	0.000339	CcSEcCtD
Pergolide—Loss of consciousness—Epirubicin—ovarian cancer	0.000291	0.000337	CcSEcCtD
Pergolide—Cough—Epirubicin—ovarian cancer	0.000289	0.000335	CcSEcCtD
Pergolide—Asthenia—Docetaxel—ovarian cancer	0.000288	0.000333	CcSEcCtD
Pergolide—Convulsion—Epirubicin—ovarian cancer	0.000287	0.000333	CcSEcCtD
Pergolide—Hypertension—Epirubicin—ovarian cancer	0.000286	0.000331	CcSEcCtD
Pergolide—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000284	0.00033	CcSEcCtD
Pergolide—Pruritus—Docetaxel—ovarian cancer	0.000284	0.000329	CcSEcCtD
Pergolide—Anaemia—Doxorubicin—ovarian cancer	0.000283	0.000328	CcSEcCtD
Pergolide—Arthralgia—Epirubicin—ovarian cancer	0.000282	0.000327	CcSEcCtD
Pergolide—Chest pain—Epirubicin—ovarian cancer	0.000282	0.000327	CcSEcCtD
Pergolide—Myalgia—Epirubicin—ovarian cancer	0.000282	0.000327	CcSEcCtD
Pergolide—Agitation—Doxorubicin—ovarian cancer	0.000282	0.000326	CcSEcCtD
Pergolide—Anxiety—Epirubicin—ovarian cancer	0.000281	0.000326	CcSEcCtD
Pergolide—Nausea—Paclitaxel—ovarian cancer	0.000281	0.000325	CcSEcCtD
Pergolide—Discomfort—Epirubicin—ovarian cancer	0.000279	0.000323	CcSEcCtD
Pergolide—Malaise—Doxorubicin—ovarian cancer	0.000276	0.00032	CcSEcCtD
Pergolide—Dry mouth—Epirubicin—ovarian cancer	0.000276	0.00032	CcSEcCtD
Pergolide—Vertigo—Doxorubicin—ovarian cancer	0.000275	0.000319	CcSEcCtD
Pergolide—Syncope—Doxorubicin—ovarian cancer	0.000275	0.000319	CcSEcCtD
Pergolide—Leukopenia—Doxorubicin—ovarian cancer	0.000274	0.000318	CcSEcCtD
Pergolide—Diarrhoea—Docetaxel—ovarian cancer	0.000274	0.000318	CcSEcCtD
Pergolide—Confusional state—Epirubicin—ovarian cancer	0.000273	0.000316	CcSEcCtD
Pergolide—Palpitations—Doxorubicin—ovarian cancer	0.000271	0.000314	CcSEcCtD
Pergolide—Oedema—Epirubicin—ovarian cancer	0.00027	0.000313	CcSEcCtD
Pergolide—Loss of consciousness—Doxorubicin—ovarian cancer	0.000269	0.000312	CcSEcCtD
Pergolide—Infection—Epirubicin—ovarian cancer	0.000269	0.000311	CcSEcCtD
Pergolide—Cough—Doxorubicin—ovarian cancer	0.000267	0.00031	CcSEcCtD
Pergolide—Shock—Epirubicin—ovarian cancer	0.000266	0.000308	CcSEcCtD
Pergolide—Convulsion—Doxorubicin—ovarian cancer	0.000266	0.000308	CcSEcCtD
Pergolide—Dizziness—Docetaxel—ovarian cancer	0.000265	0.000307	CcSEcCtD
Pergolide—Thrombocytopenia—Epirubicin—ovarian cancer	0.000265	0.000307	CcSEcCtD
Pergolide—Hypertension—Doxorubicin—ovarian cancer	0.000265	0.000307	CcSEcCtD
Pergolide—Tachycardia—Epirubicin—ovarian cancer	0.000264	0.000306	CcSEcCtD
Pergolide—Hyperhidrosis—Epirubicin—ovarian cancer	0.000261	0.000303	CcSEcCtD
Pergolide—Chest pain—Doxorubicin—ovarian cancer	0.000261	0.000302	CcSEcCtD
Pergolide—Arthralgia—Doxorubicin—ovarian cancer	0.000261	0.000302	CcSEcCtD
Pergolide—Myalgia—Doxorubicin—ovarian cancer	0.000261	0.000302	CcSEcCtD
Pergolide—Anxiety—Doxorubicin—ovarian cancer	0.00026	0.000301	CcSEcCtD
Pergolide—Discomfort—Doxorubicin—ovarian cancer	0.000258	0.000299	CcSEcCtD
Pergolide—Anorexia—Epirubicin—ovarian cancer	0.000258	0.000299	CcSEcCtD
Pergolide—Dry mouth—Doxorubicin—ovarian cancer	0.000255	0.000296	CcSEcCtD
Pergolide—Vomiting—Docetaxel—ovarian cancer	0.000255	0.000295	CcSEcCtD
Pergolide—Rash—Docetaxel—ovarian cancer	0.000253	0.000293	CcSEcCtD
Pergolide—Hypotension—Epirubicin—ovarian cancer	0.000253	0.000293	CcSEcCtD
Pergolide—Dermatitis—Docetaxel—ovarian cancer	0.000252	0.000293	CcSEcCtD
Pergolide—Confusional state—Doxorubicin—ovarian cancer	0.000252	0.000292	CcSEcCtD
Pergolide—Headache—Docetaxel—ovarian cancer	0.000251	0.000291	CcSEcCtD
Pergolide—Oedema—Doxorubicin—ovarian cancer	0.00025	0.00029	CcSEcCtD
Pergolide—Infection—Doxorubicin—ovarian cancer	0.000248	0.000288	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000246	0.000285	CcSEcCtD
Pergolide—Shock—Doxorubicin—ovarian cancer	0.000246	0.000285	CcSEcCtD
Pergolide—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000245	0.000284	CcSEcCtD
Pergolide—Insomnia—Epirubicin—ovarian cancer	0.000244	0.000283	CcSEcCtD
Pergolide—Tachycardia—Doxorubicin—ovarian cancer	0.000244	0.000283	CcSEcCtD
Pergolide—Paraesthesia—Epirubicin—ovarian cancer	0.000243	0.000281	CcSEcCtD
Pergolide—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000242	0.00028	CcSEcCtD
Pergolide—Dyspnoea—Epirubicin—ovarian cancer	0.000241	0.000279	CcSEcCtD
Pergolide—Somnolence—Epirubicin—ovarian cancer	0.00024	0.000279	CcSEcCtD
Pergolide—Anorexia—Doxorubicin—ovarian cancer	0.000238	0.000276	CcSEcCtD
Pergolide—Nausea—Docetaxel—ovarian cancer	0.000238	0.000276	CcSEcCtD
Pergolide—Dyspepsia—Epirubicin—ovarian cancer	0.000238	0.000276	CcSEcCtD
Pergolide—Decreased appetite—Epirubicin—ovarian cancer	0.000235	0.000272	CcSEcCtD
Pergolide—Hypotension—Doxorubicin—ovarian cancer	0.000234	0.000271	CcSEcCtD
Pergolide—Constipation—Epirubicin—ovarian cancer	0.000231	0.000268	CcSEcCtD
Pergolide—Pain—Epirubicin—ovarian cancer	0.000231	0.000268	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000228	0.000264	CcSEcCtD
Pergolide—Insomnia—Doxorubicin—ovarian cancer	0.000226	0.000262	CcSEcCtD
Pergolide—Paraesthesia—Doxorubicin—ovarian cancer	0.000225	0.00026	CcSEcCtD
Pergolide—Dyspnoea—Doxorubicin—ovarian cancer	0.000223	0.000258	CcSEcCtD
Pergolide—Feeling abnormal—Epirubicin—ovarian cancer	0.000223	0.000258	CcSEcCtD
Pergolide—Somnolence—Doxorubicin—ovarian cancer	0.000222	0.000258	CcSEcCtD
Pergolide—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000221	0.000256	CcSEcCtD
Pergolide—Dyspepsia—Doxorubicin—ovarian cancer	0.00022	0.000255	CcSEcCtD
Pergolide—Decreased appetite—Doxorubicin—ovarian cancer	0.000217	0.000252	CcSEcCtD
Pergolide—Pain—Doxorubicin—ovarian cancer	0.000214	0.000248	CcSEcCtD
Pergolide—Constipation—Doxorubicin—ovarian cancer	0.000214	0.000248	CcSEcCtD
Pergolide—Abdominal pain—Epirubicin—ovarian cancer	0.000214	0.000248	CcSEcCtD
Pergolide—Body temperature increased—Epirubicin—ovarian cancer	0.000214	0.000248	CcSEcCtD
Pergolide—Feeling abnormal—Doxorubicin—ovarian cancer	0.000206	0.000239	CcSEcCtD
Pergolide—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000205	0.000237	CcSEcCtD
Pergolide—Abdominal pain—Doxorubicin—ovarian cancer	0.000198	0.000229	CcSEcCtD
Pergolide—Body temperature increased—Doxorubicin—ovarian cancer	0.000198	0.000229	CcSEcCtD
Pergolide—Asthenia—Epirubicin—ovarian cancer	0.000194	0.000225	CcSEcCtD
Pergolide—Pruritus—Epirubicin—ovarian cancer	0.000191	0.000222	CcSEcCtD
Pergolide—Diarrhoea—Epirubicin—ovarian cancer	0.000185	0.000214	CcSEcCtD
Pergolide—Asthenia—Doxorubicin—ovarian cancer	0.000179	0.000208	CcSEcCtD
Pergolide—Dizziness—Epirubicin—ovarian cancer	0.000179	0.000207	CcSEcCtD
Pergolide—Pruritus—Doxorubicin—ovarian cancer	0.000177	0.000205	CcSEcCtD
Pergolide—Vomiting—Epirubicin—ovarian cancer	0.000172	0.000199	CcSEcCtD
Pergolide—Diarrhoea—Doxorubicin—ovarian cancer	0.000171	0.000198	CcSEcCtD
Pergolide—Rash—Epirubicin—ovarian cancer	0.00017	0.000198	CcSEcCtD
Pergolide—Dermatitis—Epirubicin—ovarian cancer	0.00017	0.000197	CcSEcCtD
Pergolide—Headache—Epirubicin—ovarian cancer	0.000169	0.000196	CcSEcCtD
Pergolide—Dizziness—Doxorubicin—ovarian cancer	0.000165	0.000192	CcSEcCtD
Pergolide—Nausea—Epirubicin—ovarian cancer	0.000161	0.000186	CcSEcCtD
Pergolide—Vomiting—Doxorubicin—ovarian cancer	0.000159	0.000184	CcSEcCtD
Pergolide—Rash—Doxorubicin—ovarian cancer	0.000158	0.000183	CcSEcCtD
Pergolide—Dermatitis—Doxorubicin—ovarian cancer	0.000158	0.000183	CcSEcCtD
Pergolide—Headache—Doxorubicin—ovarian cancer	0.000157	0.000182	CcSEcCtD
Pergolide—Nausea—Doxorubicin—ovarian cancer	0.000149	0.000172	CcSEcCtD
Pergolide—DRD3—Signaling Pathways—MAPK3—ovarian cancer	3.05e-06	0.000151	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	3.04e-06	0.000151	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	3.04e-06	0.000151	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—CTNNB1—ovarian cancer	3.04e-06	0.00015	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CXCL8—ovarian cancer	3.04e-06	0.00015	CbGpPWpGaD
Pergolide—HTR1A—Signaling by GPCR—AKT1—ovarian cancer	3.03e-06	0.00015	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MMP9—ovarian cancer	3.03e-06	0.00015	CbGpPWpGaD
Pergolide—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	3.02e-06	0.000149	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—HRAS—ovarian cancer	3.02e-06	0.000149	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—PTEN—ovarian cancer	3.01e-06	0.000149	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—MYC—ovarian cancer	3.01e-06	0.000149	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	2.99e-06	0.000148	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	2.98e-06	0.000147	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	2.97e-06	0.000147	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	2.97e-06	0.000147	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—MYC—ovarian cancer	2.97e-06	0.000147	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—MYC—ovarian cancer	2.97e-06	0.000147	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	2.96e-06	0.000147	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—KRAS—ovarian cancer	2.95e-06	0.000146	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—PIK3CA—ovarian cancer	2.94e-06	0.000146	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—MAPK1—ovarian cancer	2.94e-06	0.000146	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—EGFR—ovarian cancer	2.94e-06	0.000146	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—AKT1—ovarian cancer	2.94e-06	0.000145	CbGpPWpGaD
Pergolide—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	2.93e-06	0.000145	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	2.93e-06	0.000145	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PTEN—ovarian cancer	2.92e-06	0.000145	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	2.92e-06	0.000145	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	2.92e-06	0.000144	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	2.91e-06	0.000144	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	2.91e-06	0.000144	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CASP3—ovarian cancer	2.91e-06	0.000144	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—IL2—ovarian cancer	2.9e-06	0.000144	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—MAPK1—ovarian cancer	2.9e-06	0.000144	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—MAPK1—ovarian cancer	2.9e-06	0.000144	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—EGFR—ovarian cancer	2.9e-06	0.000144	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—EGFR—ovarian cancer	2.9e-06	0.000144	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	2.89e-06	0.000143	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—IL6—ovarian cancer	2.89e-06	0.000143	CbGpPWpGaD
Pergolide—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	2.89e-06	0.000143	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	2.88e-06	0.000143	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—PIK3CA—ovarian cancer	2.88e-06	0.000143	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CG—ovarian cancer	2.88e-06	0.000142	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	2.87e-06	0.000142	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	2.87e-06	0.000142	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CASP3—ovarian cancer	2.86e-06	0.000142	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	2.86e-06	0.000141	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—IL2—ovarian cancer	2.86e-06	0.000141	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—TP53—ovarian cancer	2.85e-06	0.000141	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—IL6—ovarian cancer	2.84e-06	0.000141	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—PIK3CA—ovarian cancer	2.83e-06	0.00014	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CCND1—ovarian cancer	2.83e-06	0.00014	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	2.83e-06	0.00014	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	2.83e-06	0.00014	CbGpPWpGaD
Pergolide—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	2.83e-06	0.00014	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.81e-06	0.000139	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	2.81e-06	0.000139	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	2.8e-06	0.000139	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	2.8e-06	0.000139	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—IL2—ovarian cancer	2.8e-06	0.000138	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	2.8e-06	0.000138	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—TP53—ovarian cancer	2.79e-06	0.000138	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CCND1—ovarian cancer	2.78e-06	0.000138	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	2.78e-06	0.000138	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—STAT3—ovarian cancer	2.78e-06	0.000138	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—KRAS—ovarian cancer	2.78e-06	0.000137	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—NRAS—ovarian cancer	2.78e-06	0.000137	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—STAT3—ovarian cancer	2.77e-06	0.000137	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—NRAS—ovarian cancer	2.76e-06	0.000137	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	2.76e-06	0.000136	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	2.75e-06	0.000136	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MMP9—ovarian cancer	2.75e-06	0.000136	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—TP53—ovarian cancer	2.74e-06	0.000136	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—KRAS—ovarian cancer	2.74e-06	0.000136	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—KRAS—ovarian cancer	2.74e-06	0.000136	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PTEN—ovarian cancer	2.73e-06	0.000135	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	2.73e-06	0.000135	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—HRAS—ovarian cancer	2.72e-06	0.000135	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	2.72e-06	0.000135	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	2.72e-06	0.000135	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	2.71e-06	0.000134	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MMP9—ovarian cancer	2.7e-06	0.000134	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	2.7e-06	0.000134	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	2.7e-06	0.000134	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	2.69e-06	0.000133	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PTEN—ovarian cancer	2.69e-06	0.000133	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	2.69e-06	0.000133	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MYC—ovarian cancer	2.68e-06	0.000133	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	2.68e-06	0.000132	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—HRAS—ovarian cancer	2.67e-06	0.000132	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—AKT1—ovarian cancer	2.66e-06	0.000132	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	2.66e-06	0.000132	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	2.66e-06	0.000131	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	2.65e-06	0.000131	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	2.65e-06	0.000131	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	2.64e-06	0.000131	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	2.64e-06	0.000131	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	2.63e-06	0.00013	CbGpPWpGaD
Pergolide—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	2.63e-06	0.00013	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—HRAS—ovarian cancer	2.62e-06	0.00013	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	2.62e-06	0.00013	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	2.62e-06	0.00013	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	2.62e-06	0.00013	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—TP53—ovarian cancer	2.62e-06	0.00013	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.61e-06	0.000129	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—IL6—ovarian cancer	2.61e-06	0.000129	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	2.6e-06	0.000129	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—IL2—ovarian cancer	2.6e-06	0.000129	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	2.59e-06	0.000128	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MYC—ovarian cancer	2.58e-06	0.000128	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	2.57e-06	0.000127	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MYC—ovarian cancer	2.57e-06	0.000127	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	2.57e-06	0.000127	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—TYMS—ovarian cancer	2.56e-06	0.000127	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	2.55e-06	0.000126	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—IL6—ovarian cancer	2.55e-06	0.000126	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—PIK3CA—ovarian cancer	2.54e-06	0.000126	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	2.53e-06	0.000125	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	2.53e-06	0.000125	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CD—ovarian cancer	2.53e-06	0.000125	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	2.53e-06	0.000125	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—EGFR—ovarian cancer	2.53e-06	0.000125	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—PIK3CA—ovarian cancer	2.52e-06	0.000125	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	2.52e-06	0.000125	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	2.52e-06	0.000125	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—EGFR—ovarian cancer	2.52e-06	0.000125	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—IL6—ovarian cancer	2.51e-06	0.000124	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	2.51e-06	0.000124	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—HRAS—ovarian cancer	2.5e-06	0.000124	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MYC—ovarian cancer	2.5e-06	0.000124	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	2.47e-06	0.000122	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—TP53—ovarian cancer	2.47e-06	0.000122	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—VEGFA—ovarian cancer	2.47e-06	0.000122	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MYC—ovarian cancer	2.46e-06	0.000122	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	2.46e-06	0.000122	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	2.45e-06	0.000121	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	2.45e-06	0.000121	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	2.44e-06	0.000121	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—STAT3—ovarian cancer	2.44e-06	0.000121	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—NRAS—ovarian cancer	2.44e-06	0.000121	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—TP53—ovarian cancer	2.44e-06	0.000121	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—TP53—ovarian cancer	2.44e-06	0.000121	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	2.43e-06	0.00012	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	2.41e-06	0.000119	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	2.41e-06	0.000119	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—AKT1—ovarian cancer	2.4e-06	0.000119	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—STAT3—ovarian cancer	2.4e-06	0.000119	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—NRAS—ovarian cancer	2.4e-06	0.000119	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—IL6—ovarian cancer	2.4e-06	0.000119	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—KRAS—ovarian cancer	2.39e-06	0.000118	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	2.39e-06	0.000118	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	2.38e-06	0.000118	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—KRAS—ovarian cancer	2.38e-06	0.000118	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—HRAS—ovarian cancer	2.36e-06	0.000117	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—AKT1—ovarian cancer	2.35e-06	0.000116	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	2.35e-06	0.000116	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	2.35e-06	0.000116	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MAPK3—ovarian cancer	2.33e-06	0.000116	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—HRAS—ovarian cancer	2.33e-06	0.000115	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—HRAS—ovarian cancer	2.33e-06	0.000115	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—AKT1—ovarian cancer	2.32e-06	0.000115	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	2.31e-06	0.000114	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	2.3e-06	0.000114	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	2.27e-06	0.000113	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	2.27e-06	0.000113	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MYC—ovarian cancer	2.27e-06	0.000112	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—IL6—ovarian cancer	2.26e-06	0.000112	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	2.25e-06	0.000111	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MYC—ovarian cancer	2.23e-06	0.000111	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—IL6—ovarian cancer	2.23e-06	0.00011	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—IL6—ovarian cancer	2.23e-06	0.00011	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MAPK1—ovarian cancer	2.22e-06	0.00011	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—EGFR—ovarian cancer	2.22e-06	0.00011	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—AKT1—ovarian cancer	2.21e-06	0.000109	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	2.21e-06	0.000109	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CB—ovarian cancer	2.2e-06	0.000109	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—TP53—ovarian cancer	2.2e-06	0.000109	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	2.19e-06	0.000109	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MYC—ovarian cancer	2.19e-06	0.000108	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	2.19e-06	0.000108	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	2.18e-06	0.000108	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—EGFR—ovarian cancer	2.18e-06	0.000108	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	2.18e-06	0.000108	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	2.18e-06	0.000108	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	2.14e-06	0.000106	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	2.14e-06	0.000106	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	2.12e-06	0.000105	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—TP53—ovarian cancer	2.12e-06	0.000105	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—TP53—ovarian cancer	2.11e-06	0.000105	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	2.1e-06	0.000104	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—KRAS—ovarian cancer	2.1e-06	0.000104	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	2.09e-06	0.000103	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	2.09e-06	0.000103	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—AKT1—ovarian cancer	2.08e-06	0.000103	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—AKT1—ovarian cancer	2.07e-06	0.000103	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—CAV1—ovarian cancer	2.07e-06	0.000102	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—KRAS—ovarian cancer	2.06e-06	0.000102	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PIK3CA—ovarian cancer	2.06e-06	0.000102	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—AKT1—ovarian cancer	2.06e-06	0.000102	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—AKT1—ovarian cancer	2.06e-06	0.000102	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—TP53—ovarian cancer	2.05e-06	0.000102	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MYC—ovarian cancer	2.03e-06	0.000101	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—HRAS—ovarian cancer	2.03e-06	0.0001	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—TP53—ovarian cancer	2.02e-06	0.0001	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	2.02e-06	0.0001	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—HRAS—ovarian cancer	2.02e-06	0.0001	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—IL6—ovarian cancer	2.01e-06	9.96e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	1.99e-06	9.84e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	1.99e-06	9.84e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	1.96e-06	9.72e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—IL6—ovarian cancer	1.94e-06	9.62e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	1.93e-06	9.57e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—IL6—ovarian cancer	1.93e-06	9.57e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	1.93e-06	9.54e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PTEN—ovarian cancer	1.91e-06	9.43e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	1.9e-06	9.38e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.88e-06	9.31e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—IL6—ovarian cancer	1.88e-06	9.31e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	1.88e-06	9.29e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—TP53—ovarian cancer	1.86e-06	9.23e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	1.86e-06	9.19e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	1.86e-06	9.19e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—IL6—ovarian cancer	1.85e-06	9.16e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—TP53—ovarian cancer	1.83e-06	9.08e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—TP53—ovarian cancer	1.8e-06	8.89e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—AKT1—ovarian cancer	1.79e-06	8.87e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—AKT1—ovarian cancer	1.78e-06	8.83e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—HRAS—ovarian cancer	1.78e-06	8.82e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—HRAS—ovarian cancer	1.75e-06	8.68e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	1.73e-06	8.59e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	1.72e-06	8.54e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	1.72e-06	8.5e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	1.71e-06	8.45e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—IL6—ovarian cancer	1.71e-06	8.45e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—AKT1—ovarian cancer	1.68e-06	8.34e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—IL6—ovarian cancer	1.68e-06	8.31e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—TP53—ovarian cancer	1.67e-06	8.26e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.65e-06	8.19e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—IL6—ovarian cancer	1.64e-06	8.14e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	1.6e-06	7.9e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—AKT1—ovarian cancer	1.57e-06	7.79e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—AKT1—ovarian cancer	1.55e-06	7.67e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—IL6—ovarian cancer	1.53e-06	7.56e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	1.52e-06	7.51e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.44e-06	7.14e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	1.41e-06	6.97e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.34e-06	6.65e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PTEN—ovarian cancer	1.25e-06	6.17e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—AKT1—ovarian cancer	1.1e-06	5.44e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CA—ovarian cancer	8.79e-07	4.35e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—AKT1—ovarian cancer	7.18e-07	3.55e-05	CbGpPWpGaD
